Acetaminophen Co-Formulation for Preventing and Reducing the Risk of Acetaminophen-Induced Liver Toxicity
- Detailed Technology Description
- The present disclosure relates generally to a pharmaceutical compositions and methods of reducing acetaminophen-induced liver toxicity.
- Countries
- United States
- Application No.
- 8685956
- *Abstract
-
The present disclosure relates generally to a pharmaceutical compositions and methods of reducing acetaminophen-induced liver toxicity. The disclosure includes pharmaceutical compositions including acetaminophen and one or more components selected from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof. The disclosure also relates to methods of reducing acetaminophen-induced liver toxicity in a subject by administering or co-administering one or more of S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof, with acetaminophen to a subject.
For more information about this technology, please contact the University of Illinois at Urbana-Champaign Office of Technology Management at otm@illinois.edu.
- *IP Issue Date
- None
- *IP Type
- Utility
- Country/Region
- USA
